“We believed this was likely given that on the FDA informed the company it had identified deficiencies in its sNDA, which we had viewed as a potential precursor to the company receiving a CRL. According to the press release (VNDA is not holding a conference call to discuss the CRL), the FDA indicated the improvement in sleep seen with Hetlioz treatment was “of unclear clinical significance.” VNDA also noted the CRL contains additional observations regarding the sNDA, but the company did not provide specifics. It is unclear what the next steps are for this program from a timing/clinical perspective, but our view on JLD has been whether or not this is a commercially viable indication for VNDA to develop Hetlioz for.”
According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -11.8% and a 26.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vanda with a $18 average price target.
Based on Vanda’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $11.53 million. In comparison, last year the company had a net profit of $4.61 million.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.